title: Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
abstract: BACKGROUND
  Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody.
  
  
  METHODS
  Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation.
  
  
  RESULTS
  The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in < or =21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months.
  
  
  CONCLUSIONS
  Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.
authors.affiliation: Department of Obstetrics and Gynecology, University of Alabama at Birmingham, USA.
authors.forename: R D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: E E
authors.initials: EE
authors.lastname: Partridge
authors.forename: M B
authors.initials: MB
authors.lastname: Khazaeli
authors.forename: G
authors.initials: G
authors.lastname: Plott
authors.forename: M
authors.initials: M
authors.lastname: Austin
authors.forename: L
authors.initials: L
authors.lastname: Kilgore
authors.forename: C D
authors.initials: CD
authors.lastname: Russell
authors.forename: T
authors.initials: T
authors.lastname: Liu
authors.forename: W E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: J
authors.initials: J
authors.lastname: Schlom
authors.forename: A F
authors.initials: AF
authors.lastname: LoBuglio
authors.forename: R F
authors.initials: RF
authors.lastname: Meredith
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018771:Arthralgia / Q000209:etiology; D001853:Bone Marrow / Q000473:pathology / Q000528:radiation effects; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008187:Lutetium; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*; D010976:Platelet Count; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D011868:Radioisotopes
chemical_list: D000911:Antibodies, Monoclonal; D011868:Radioisotopes; D008187:Lutetium